Research on human brain development and neurological diseases is limited by the lack of advanced experimental in vitro models that truly recapitulate the complexity of the human brain. Furthermore, animal models of human neurodegenerative diseases have failed dramatically, and the success rate of clinical trials based on these models has been disappointing. Here, we describe a novel and robust human brain organoid system that is highly specific to the midbrain derived from regionally patterned neuroepithelial stem cells. These human midbrain organoids contain spatially organized groups of dopaminergic neurons, which make them an attractive model to study Parkinson's disease. Midbrain organoids are characterized in detail for neuronal, astroglial and oligodendrocyte differentiation.
Introduction
With the development of methods to generate induced pluripotent stem cells (iPSCs) from somatic cells (1, 2), human cells with the potential to generate all body cell types in vitro became available. This advance led to tremendous progress in the development of protocols for the differentiation of iPSCs into various human cell types. Additionally, disease-specific human iPSCs and their derived cell types are now widely used for in vitro disease modeling.
However, particularly with regard to neuronal diseases, it is of importance to consider that the human brain is an extremely complex, three-dimensional structure. Consequently, the investigation of its development and modeling of disease processes in traditional, twodimensional cultures has strong limitations. It has been demonstrated that the presence of a 3D matrix promotes many biologically relevant functions, such as differentiation capability (3) (4) (5) (6) , cellular signaling, and lineage specification (4, 7, 8) , which are otherwise not observed in 2D monolayer cell cultures (9) . Additionally, impaired cell-cell and cell-matrix interactions have been shown (10) . These observations have, in recent years, prompted the use of human iPSCs for the generation of three-dimensional in vitro models of complete organs, the so-called organoids.
These organoid technologies have been pioneered for the small intestine (11) and later extended also to other organs or parts of organs (12) . Recently, protocols for the generation of human brain-like organoids have been developed, including protocols for cerebral (13) , cerebellar (14) and forebrain organoids (15) . These organoids provide a proof-of-concept that human iPSCs can indeed differentiate into various cell types and even self-organize with a specific spatial orientation, which recapitulates key features of the human brain. These brain organoids have been used successfully to model a genetic form of microcephaly (13) as well as Zika virusinduced microcephaly (15) . Importantly, thus far, all brain organoids have been generated directly from iPSCs; however, evidence suggesting that these organoids could also be derived from more fate-restricted neural stem cells is lacking. The utilization of neural stem cells as the starting population has the advantage that already patterned cells differentiate faster and can be cultured more efficiently (cheaper, faster cell doublings, ease of handling, etc.). Furthermore, while the generation of certain brain structures, such as the cerebral cortex or cerebellum, is meanwhile well described, a higher degree of pre-patterning seems to be required for the generation of other highly specialized structures. This is particularly true for brain regions severely affected in neurodegenerative disorders, such as Alzheimer's disease (hippocampus) or Parkinson's disease (substantia nigra).
To address these challenges, we used our previously described human neuroepithelial stem cell (NESC) culture system (16) and differentiated these NESCs under dynamic conditions into human midbrain specific organoids.
Results

Generation of human midbrain-specific organoids
Previously described neuroepithelial stem cells (16) were used as the starting population for the generation of human midbrain organoids. Compared to iPSCs as a starting population, NESCs are already patterned towards midbrain/hindbrain identity. Therefore, a faster and more complete differentiation into midbrain organoids was expected.
Typically, NESCs express the neural progenitor markers SOX1, SOX2, PAX6, and NESTIN prior to organoid generation ( Fig. S1A ). Cells were seeded on round-bottom ultralow adhesion 96-well plates enabling the cells to form three-dimensional colonies. They were cultured in the presence of the GSK3b inhibitor CHIR99021 to stimulate the canonical WNT signaling pathway, and the SHH pathway was activated using purmorphamine (PMA). On day 8, the three-dimensional NESC colonies were embedded into droplets of Matrigel for structural support, and two days after, specification into midbrain organoids was initiated by changing the media to differentiation media. We kept the organoids in 10cm Petri dishes for short-term cultures or in ultralow adhesion 24-well plates for long-term cultures and placed them on an orbital shaker rotating at approximately 80 rpm ( Fig. 1A) .
At the early stages (27 days), midbrain organoids widely expressed the cell proliferation marker Ki67, which decreases upon maturation ( Fig. 1B ). Furthermore, young organoids expressed the neural progenitor marker SOX2, which also decreases during maturation and becomes more regionally restricted, resembling the formation of a stem cell niche (Fig. 1C ). Although consistent with previous findings (13, 17) , we found substantial cell death in the core of the organoids, which resulted from the lack of nutrient support in the center of the organoid. In general, we did not observe high levels of apoptotic cell death, revealed by staining of the marker cleaved caspase-3 (CC3). The basic level of apoptosis that was detectable did not change during the course of differentiation ( Fig. S1B ). Importantly, we were able to reproduce the generation of midbrain organoids from NESCs without significant variation.
Neuronal differentiation and self-organization of human neuroepithelial stem cell derived midbrain organoids
After showing a decrease of proliferation and stem cell identity, we assessed neuronal differentiation. Because we are particularly interested in the future utilization of midbrain organoids for in vitro modeling of Parkinson's disease, we also investigated the specification of midbrain dopaminergic neurons (mDNs). We were able to see robust differentiation into TUJ1 positive neurons and TH positive DNs. These stainings revealed the formation of a complex neuronal network ( Fig In previous studies, it has been repeatedly shown that stem cells exhibit an enormous potential to self-organize into complex heterogeneous brain organoids (13, 14, 18, 19) . To examine the degree of spatial organization in NESC-derived midbrain organoids, we evaluated the distribution pattern DA neuronal markers TUJ1/TH and depicted the results using surface plots.
Strikingly, we found that DA neurons form clearly specified clusters within midbrain organoids ( Fig. 2H, 2I ). To further demonstrate the identity of TH positive neurons as dopaminergic, we analyzed their ability to produce the neurotransmitter dopamine. Immunostainings of mature organoids demonstrated the presence of dopamine and TH-double positive cells ( Fig. 2J ).
These results indicated that mDNs of NESC-derived organoids self-organize into a complex, spatially patterned and functional neuronal tissue.
Glial differentiation in midbrain organoids
During the development of the fetal human brain, neural tube-derived cells not only differentiate into neurons but also into glia cells, including astrocytes and oligodendrocytes.
Therefore, we investigated the presence of these glia cells in the midbrain organoids. In good agreement with brain development, where glia differentiation temporally follows neuronal differentiation, we were unable to detect significant amounts of glia cells in young organoids (day 27). However, in more mature organoids (day 61), we observed astrocytes positive for the markers S100β and GFAP. Interestingly, we obtained populations of astrocytes in both a quiescent state (negative for GFAP) and a reactive state characterized by GFAP expression ( Fig. 3A, B ). Moreover, we detected a fraction of cells that differentiated into O4-positive oligodendrocytes at day 44. Furthermore, interestingly, these oligodendrocytes typically showed a spatially asymmetric distribution within the organoids (Fig. S3A ). In the central nervous system, mature oligodendrocytes form myelin sheaths that enwrap axons to accelerate the transmission of action potentials along axons. To analyze if the oligodendrocytes within the midbrain organoids are able to execute their actual function, i.e., formation of myelin sheets, we performed immunofluorescence staining against 2',3'-cyclic-nucleotide 3'phosphodiesterase (CNPase), a myelin-associated enzyme together with the neuronal marker TUJ1. A 3D surface reconstruction of these stainings revealed numerous TUJ1-positive neurites that were ensheathed by myelin sheets of CNPase-positive oligodendrocytes ( Fig. 3C and S3B). Interestingly, these neurites often showed gaps of ensheathment, resembling the formation of nodes of Ranvier ( Fig. 3C ) that allow for saltatory fast neuronal transmission.
Functionality of midbrain organoids
One important requirement for neuronal transmission is the development of a mature neuronal network via the formation of synaptic connections. Therefore, synaptic connectivity was investigated using immunohistological staining against the presynaptic marker synaptophysin and the postsynaptic marker PSD95 at day 61. A subsequent 3D surface reconstruction demonstrated not only the formation of numerous pre-and postsynaptic puncta but also multiple synaptic connections ( Fig. 3D and S3C ). Synaptic connections have been developed between different neurites, indicated by the direct contact of synaptophysin-positive presynapses with PSD95-positive postsynapses ( Fig. 3E ). Accordingly, midbrain organoids exhibit the ability to forward signals via synaptic connections and thus fulfill the prerequisite for being electrophysiologically functional.
To further confirm their functionality and neuronal network activity, we performed Fluo-4AM calcium imaging on whole organoids. We measured the spontaneous neuronal activity based on calcium transients evoked by action potentials (Fig. 4A, B, Fig S4, video S1). Notably, some of the fluorescent traces showed regular firing patterns, which were indicative of tonic electrophysiological activity and resembled the pacemaker activity of dopaminergic neurons (20, 21) . In addition to calcium imaging, a multielectrode array (MEA) system was used to examine the electrophysiological activity. This methodology allows non-invasive recordings of extracellular field potentials generated by action potentials. At day 60-70, the midbrain organoids were placed on a grid of 16 electrodes in a 48-well tissue culture plate ( Fig. 4C ). 
Discussion
One of the main limitations in neuroscience and the modeling of neurological diseases is the lack of advanced experimental in vitro models that truly recapitulate the complexity of the human brain. Currently, although pre-clinical tests in animals suggest that a treatment will be safe and effective for a certain disease in humans, a high percentage of potential drug candidates fail in clinical trials. As an example, the failure rate for Alzheimer's disease drug development is an astonishing 99.6% (22) . Here, we have presented a novel human brain organoid system that is highly specific to the midbrain. These midbrain organoids contain spatially patterned groups of dopaminergic neurons, which make them an attractive model for the study of Parkinson's disease. Midbrain organoids are characterized in detail with regard to neuronal differentiation and activity as well as for astroglial and oligodendrocyte differentiation.
The presence of astrocytes is crucial for the formation of synapses and regular neuronal activity (23) . Astrocytes are specified later in development than neurons (24, 25) . Accordingly, midbrain organoids show a robust astrocyte immunoreactivity only after 61 days of differentiation. Furthermore, synaptic connections, consisting of a direct contact between preand post-synapses, are detectable in the midbrain organoids. These synaptic contacts are the prerequisite for electrophysiological and neuronal network functionality, which we indeed detected in the midbrain organoids by Ca2+ imaging and multi-electrode array measurements.
Additionally, fast information transmission between neurons depends on axonal myelination, which is achieved by oligodendrocytes. In most stem cell based differentiation protocols, the differentiation into oligodendrocytes is extremely inefficient (26, 27) . However, in the present approach, we achieved a robust differentiation into oligodendrocytes and a high degree of neurite myelination. Neurites in these midbrain organoids are ensheathed by oligodendrocytes and even structures, such as the nodes of Ranvier that are of critical importance for saltatory transmission of signals in axons (28) , become apparent.
Compared to other pioneering human brain organoid systems, we are able to generate organoids of a remarkable size (up to 2 mm in diameter) with a high reproducibility.
Furthermore, we provide a detailed characterization of synapse formation and myelination, which has not been achieved in human brain organoids so far. Importantly, in contrast to all other human brain organoid systems, our starting population of cells are not iPSCs but neuroepithelial stem cells (16) , which allows us to achieve a faster and more directed differentiation. Our approach is fully focused on the midbrain, as shown by the abundant presence of neurons with midbrain dopaminergic neuron identity. These neurons are not only able to produce dopamine but are also asymmetrically distributed in a discrete cluster. This asymmetry mirrors a unique feature of the human brain where the soma of dopaminergic neurons reside in the substantia nigra.
The presented human midbrain organoids have a great potential to be used for in vitro modeling of diseases that strongly affect the human midbrain, particularly Parkinson's disease (29) . The midbrain organoids may be used for investigating toxin-induced PD, e.g., after exposure to MPTP (30, 31) or rotenone (31) and genetic forms of PD. In particular, the genetic forms, which are caused by mutations in genes, such as LRRK2 (32) or Pink1 (33), could be modeled using patient-specific iPSC derived NESCs differentiated into midbrain organoids. Patientspecific midbrain organoids could reveal specific phenotypes that are not abundant in 2D cultures and therefore may be used for mechanistic studies and drug testing. Importantly, such a pipeline would be fully suitable for approaches in personalized medicine (34, 35) .
Neurodegenerative disorders, such as PD, are typically considered to be age-associated diseases (36, 37) . However, there is accumulating evidence that PD has a strong neurodevelopmental component that probably defines the susceptibility to develop the disease (38, 39) . This finding supports the importance of human brain development models to investigate the disease underlying mechanisms. Currently, available protocols for the generation of brain organoids typically result in structures that resemble the developing fetal human brain (13, 15) . Remarkably, the presented midbrain organoids exhibit a ring of neural stem cells in the center of the organoid structure, reminiscent of the stem cell niche of the ventricular / subventricular zone. Therefore, the midbrain organoids not only enable the in vitro modeling of PD and drug testing but also the study of the developmental aspects of the disease.
To date, the development of therapies against such neurodegenerative disorders largely depends on animal models. However, over the last decades, numerous therapies that showed promising results in mice failed in clinical trials. These findings support the concept that mice are not suitable to mimic human neurodegenerative diseases. The reasons for this are numerous.
As an example, a study comparing the gene expression profile of mouse models for Parkinson's disease, Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis to the corresponding human diseases revealed an extremely weak enrichment for deregulated gene sets (40) . Interestingly, concerning the gene expression pattern, even healthy human aging seems to be more closely related to the named diseases than the corresponding mouse models (40) . Additionally, many neurodegenerative diseases in humans simply do not occur naturally in mice. The available toxin-induced models and the genetic models are either rather artificial or have rather weak phenotypes and have not been predictive of the human response (41) (42) (43) .
This finding clearly implies that the underlying disease mechanisms and biology are very likely to be dramatically different between the two species.
Altogether, these findings may explain the weak performance of mouse-based translational therapies for neurodegenerative diseases and underscore that new, human specific models are strongly needed. The presented midbrain organoid system along with other models may be a first step towards a more human-specific, probably even personalized, era of advanced disease modeling and therapy development.
Materials and Methods
Midbrain organoid culture
The hiPSC-derived hNESCs were cultured as previously described (16) . On day 0 of the organoid culture, hNESCs at passage <20 were treated with accutase for 5 min at 37°C, On day 8 of the organoid culture, the 3D colonies were transferred to droplets of hESCqualified Matrigel (BD Bioscience) as previously described (17) . Droplets were cultured in N2B27 maintenance media either in 10-cm Petri dishes for short-term cultures or in ultra-low attachment 24-well plates (Corning) with one droplet per well for long-term cultures. On day 10, differentiation was initiated with N2B27 media supplemented with 10 ng/ml hBDNF (Peprotech), 10 ng/ml hGDNF (Peprotech), 500 µM dbcAMP (Peprotech), 200 µM ascorbic acid (Sigma), and 1 ng/ml TGF-β3 (Peprotech). Additionally, 1 µM purmorphamine (Enzo Life Science) was added to this medium for an additional 6 days. On day 14 of the organoid culture, the plates were placed on an orbital shaker (IKA), rotating at 80 rpm, in an incubator (5% CO2, 37°C) and the organoids were kept in culture with media changes every second or third day.
Immunohistochemical analysis
Organoids were fixed with 4 % paraformaldehyde overnight at RT and washed 3x with PBS for 1 h. Afterwards, they were embedded in 3 % low-melting point agarose in PBS and incubated for 15 min at 37 °C, followed by 30 minutes incubation at RT. The solid agarose (1:400, Sigma). After incubation with the primary antibodies, sections were washed three times in 0.05 % Triton X-100 and blocked for 30 min at RT on a shaker, followed by incubation with the secondary antibodies in 0.1% Triton X-100 (1:1000). All secondary antibodies (Invitrogen) were conjugated to Alexa Fluor fluorochromes. Dopamine was detected using a STAINperfect Immunostaining Kit (ImmuSmol) according to manufacturer's protocol. Sections were costained with chicken anti-TH primary antibody (Abcam), and nuclei were counterstained with Hoechst 33342 (Invitrogen). Sections were mounted in Fluoromount-G mounting medium (Southern Biotech) and analyzed with a confocal laser scanning microscope (Zeiss LSM 710).
Images were further processed with Zen Software (Zeiss) and ImageJ. Three-dimensional surface reconstructions of confocal z-stacks were created using Imaris software (Bitplane). The asymmetric distribution of DNs was assessed based on fluorescence intensities with the ImageJ Interactive 3D surface plot plugin.
Quantitative real-time PCR
Total RNA was isolated from 48 days-old organoids. Typically, five organoids were pooled for one isolation. For dissociation, the organoids were washed once with PBS and lysed with QIAzol lysis reagent (Qiagen), passed through a needle three times and homogenized with QIAshredder columns (Qiagen). RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Subsequently, isolated RNA was reverse- Tool (Axion BioSystems) was used to analyze the spike raster plots. Electrodes with an average of ≥5 spikes/min were defined as active. The spike count files generated from the recordings were used to calculate the number of spikes/active electrode/measurement. Further details regarding the MEA system were previously described (45) . 
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